-
Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines
•
Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB 550 million (USD 75.04 million). The round was led by Yangzhou Guojin Investment Group Co. Ltd and Kingray Capital, both renowned healthcare funds. The proceeds will be used to enhance the development and commercialization of…
-
Alebund Pharmaceuticals’ AP306 Earns Breakthrough Designation for Chronic Kidney Disease
•
Alebund Pharmaceuticals, based in Shanghai, has announced that its drug candidate AP306 (EOS789), a pan-inhibitor of phosphate transporter proteins NaPi-IIb, PiT-1, and PiT-2, has been granted breakthrough therapy designation (BTD) by the Center for Drug Evaluation. The drug is intended for the treatment of chronic kidney disease hyperphosphatemia. As the…
-
Alebund Pharmaceuticals Secures Exclusive Rights to Roche’s Mircera in China
•
Shanghai-based Alebund Pharmaceuticals has entered into a commercialization agreement with Swiss pharmaceutical giant Roche (SWX: ROG), securing exclusive promotion rights to Mircera (methoxy polyethylene glycol-epoetin beta) in mainland China. The financial terms of the deal remain undisclosed, highlighting the strategic nature of the partnership without revealing specific monetary details. Mircera:…
-
Alebund Pharmaceuticals Secures $29M in Pre-Series C Funding and $116M Loan for R&D and Manufacturing
•
Shanghai-based Alebund Pharmaceuticals has announced the completion of a pre-Series C financing round worth RMB 200 million (USD 29 million). This funding is supported by a consortium of investors including Yangzhou Guojin Investment, Jiangsu Dingxin Capital, Yangzhou Longchuan Holdings, a leading international sovereign fund, Lilly Asia Ventures, Quan Capital, 3H…
